Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer

Sho Nambara, Takaaki Masuda, Miki Nishio, Shotaro Kuramitsu, Taro Tobo, Yushi Ogawa, Qingjiang Hu, Tomohiro Iguchi, Yousuke Kuroda, Shuhei Ito, Hidetoshi Eguchi, Keishi Sugimachi, Hiroshi Saeki, Eiji Oki, Yoshihiko Maehara, Akira Suzuki, Koshi Mimori

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Yes-associated protein 1 (YAP1) acts as an oncogene through dephosphorylation and nuclear translocation, and nuclear accumulation of YAP1 is associated with poor prognosis in gastric cancer (GC). We previously identified ivermectin, an antiparasitic drug, as a YAP1 inhibitor. Here, we aimed to clarify whether ivermectin had antitumor effects on GC through inhibition of YAP1. First, we evaluated the antiproliferative effects of ivermectin on human GC cells using in vitro proliferation assays and a xenograft mouse model. YAP1-knockdown assays were performed to assess whether the sensitivity to ivermectin depended on YAP1 expression. Next, we explored the mechanism through which ivermectin regulated YAP1 expression or localization by immunoblotting and reverse transcription-quantitative polymerase chain reaction for YAP1 and the downstream gene CTGF. Finally, the clinical significance of YAP1 expression was examined using three independent GC datasets. We found that MKN1 GC cells were most sensitive to ivermectin, whereas MKN7 cells were most resistant. In MKN1 xenografts, ivermectin suppressed tumor growth, and the sensitivity of MKN1 cells to ivermectin was decreased by YAP1 knockdown. Ivermectin inhibited YAP1 nuclear expression and CTGF expression in MKN1 cells but not MKN7 cells. Moreover, ivermectin decreased YAP1 mRNA expression, thereby inhibiting nuclear accumulation of YAP1 in MKN1 cells. In survival analysis, low YAP1 mRNA expression was associated with a better prognosis in three independent GC datasets. In conclusion, we identified ivermectin as a potential antitumor agent and found a promising novel therapeutic strategy for inhibition of GC progression by blocking YAP1 expression.

Original languageEnglish
Pages (from-to)107666-107677
Number of pages12
JournalOncotarget
Volume8
Issue number64
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Antiparasitic Agents
Ivermectin
Stomach Neoplasms
Proteins
Heterografts
Messenger RNA
Survival Analysis
Nuclear Proteins
Oncogenes
Immunoblotting
Antineoplastic Agents

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. / Nambara, Sho; Masuda, Takaaki; Nishio, Miki; Kuramitsu, Shotaro; Tobo, Taro; Ogawa, Yushi; Hu, Qingjiang; Iguchi, Tomohiro; Kuroda, Yousuke; Ito, Shuhei; Eguchi, Hidetoshi; Sugimachi, Keishi; Saeki, Hiroshi; Oki, Eiji; Maehara, Yoshihiko; Suzuki, Akira; Mimori, Koshi.

In: Oncotarget, Vol. 8, No. 64, 01.01.2017, p. 107666-107677.

Research output: Contribution to journalArticle

Nambara, S, Masuda, T, Nishio, M, Kuramitsu, S, Tobo, T, Ogawa, Y, Hu, Q, Iguchi, T, Kuroda, Y, Ito, S, Eguchi, H, Sugimachi, K, Saeki, H, Oki, E, Maehara, Y, Suzuki, A & Mimori, K 2017, 'Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer', Oncotarget, vol. 8, no. 64, pp. 107666-107677. https://doi.org/10.18632/oncotarget.22587
Nambara, Sho ; Masuda, Takaaki ; Nishio, Miki ; Kuramitsu, Shotaro ; Tobo, Taro ; Ogawa, Yushi ; Hu, Qingjiang ; Iguchi, Tomohiro ; Kuroda, Yousuke ; Ito, Shuhei ; Eguchi, Hidetoshi ; Sugimachi, Keishi ; Saeki, Hiroshi ; Oki, Eiji ; Maehara, Yoshihiko ; Suzuki, Akira ; Mimori, Koshi. / Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. In: Oncotarget. 2017 ; Vol. 8, No. 64. pp. 107666-107677.
@article{713a912b9ccf4692b9502b54227f5478,
title = "Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer",
abstract = "Yes-associated protein 1 (YAP1) acts as an oncogene through dephosphorylation and nuclear translocation, and nuclear accumulation of YAP1 is associated with poor prognosis in gastric cancer (GC). We previously identified ivermectin, an antiparasitic drug, as a YAP1 inhibitor. Here, we aimed to clarify whether ivermectin had antitumor effects on GC through inhibition of YAP1. First, we evaluated the antiproliferative effects of ivermectin on human GC cells using in vitro proliferation assays and a xenograft mouse model. YAP1-knockdown assays were performed to assess whether the sensitivity to ivermectin depended on YAP1 expression. Next, we explored the mechanism through which ivermectin regulated YAP1 expression or localization by immunoblotting and reverse transcription-quantitative polymerase chain reaction for YAP1 and the downstream gene CTGF. Finally, the clinical significance of YAP1 expression was examined using three independent GC datasets. We found that MKN1 GC cells were most sensitive to ivermectin, whereas MKN7 cells were most resistant. In MKN1 xenografts, ivermectin suppressed tumor growth, and the sensitivity of MKN1 cells to ivermectin was decreased by YAP1 knockdown. Ivermectin inhibited YAP1 nuclear expression and CTGF expression in MKN1 cells but not MKN7 cells. Moreover, ivermectin decreased YAP1 mRNA expression, thereby inhibiting nuclear accumulation of YAP1 in MKN1 cells. In survival analysis, low YAP1 mRNA expression was associated with a better prognosis in three independent GC datasets. In conclusion, we identified ivermectin as a potential antitumor agent and found a promising novel therapeutic strategy for inhibition of GC progression by blocking YAP1 expression.",
author = "Sho Nambara and Takaaki Masuda and Miki Nishio and Shotaro Kuramitsu and Taro Tobo and Yushi Ogawa and Qingjiang Hu and Tomohiro Iguchi and Yousuke Kuroda and Shuhei Ito and Hidetoshi Eguchi and Keishi Sugimachi and Hiroshi Saeki and Eiji Oki and Yoshihiko Maehara and Akira Suzuki and Koshi Mimori",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.22587",
language = "English",
volume = "8",
pages = "107666--107677",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "64",

}

TY - JOUR

T1 - Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer

AU - Nambara, Sho

AU - Masuda, Takaaki

AU - Nishio, Miki

AU - Kuramitsu, Shotaro

AU - Tobo, Taro

AU - Ogawa, Yushi

AU - Hu, Qingjiang

AU - Iguchi, Tomohiro

AU - Kuroda, Yousuke

AU - Ito, Shuhei

AU - Eguchi, Hidetoshi

AU - Sugimachi, Keishi

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Maehara, Yoshihiko

AU - Suzuki, Akira

AU - Mimori, Koshi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Yes-associated protein 1 (YAP1) acts as an oncogene through dephosphorylation and nuclear translocation, and nuclear accumulation of YAP1 is associated with poor prognosis in gastric cancer (GC). We previously identified ivermectin, an antiparasitic drug, as a YAP1 inhibitor. Here, we aimed to clarify whether ivermectin had antitumor effects on GC through inhibition of YAP1. First, we evaluated the antiproliferative effects of ivermectin on human GC cells using in vitro proliferation assays and a xenograft mouse model. YAP1-knockdown assays were performed to assess whether the sensitivity to ivermectin depended on YAP1 expression. Next, we explored the mechanism through which ivermectin regulated YAP1 expression or localization by immunoblotting and reverse transcription-quantitative polymerase chain reaction for YAP1 and the downstream gene CTGF. Finally, the clinical significance of YAP1 expression was examined using three independent GC datasets. We found that MKN1 GC cells were most sensitive to ivermectin, whereas MKN7 cells were most resistant. In MKN1 xenografts, ivermectin suppressed tumor growth, and the sensitivity of MKN1 cells to ivermectin was decreased by YAP1 knockdown. Ivermectin inhibited YAP1 nuclear expression and CTGF expression in MKN1 cells but not MKN7 cells. Moreover, ivermectin decreased YAP1 mRNA expression, thereby inhibiting nuclear accumulation of YAP1 in MKN1 cells. In survival analysis, low YAP1 mRNA expression was associated with a better prognosis in three independent GC datasets. In conclusion, we identified ivermectin as a potential antitumor agent and found a promising novel therapeutic strategy for inhibition of GC progression by blocking YAP1 expression.

AB - Yes-associated protein 1 (YAP1) acts as an oncogene through dephosphorylation and nuclear translocation, and nuclear accumulation of YAP1 is associated with poor prognosis in gastric cancer (GC). We previously identified ivermectin, an antiparasitic drug, as a YAP1 inhibitor. Here, we aimed to clarify whether ivermectin had antitumor effects on GC through inhibition of YAP1. First, we evaluated the antiproliferative effects of ivermectin on human GC cells using in vitro proliferation assays and a xenograft mouse model. YAP1-knockdown assays were performed to assess whether the sensitivity to ivermectin depended on YAP1 expression. Next, we explored the mechanism through which ivermectin regulated YAP1 expression or localization by immunoblotting and reverse transcription-quantitative polymerase chain reaction for YAP1 and the downstream gene CTGF. Finally, the clinical significance of YAP1 expression was examined using three independent GC datasets. We found that MKN1 GC cells were most sensitive to ivermectin, whereas MKN7 cells were most resistant. In MKN1 xenografts, ivermectin suppressed tumor growth, and the sensitivity of MKN1 cells to ivermectin was decreased by YAP1 knockdown. Ivermectin inhibited YAP1 nuclear expression and CTGF expression in MKN1 cells but not MKN7 cells. Moreover, ivermectin decreased YAP1 mRNA expression, thereby inhibiting nuclear accumulation of YAP1 in MKN1 cells. In survival analysis, low YAP1 mRNA expression was associated with a better prognosis in three independent GC datasets. In conclusion, we identified ivermectin as a potential antitumor agent and found a promising novel therapeutic strategy for inhibition of GC progression by blocking YAP1 expression.

UR - http://www.scopus.com/inward/record.url?scp=85037360327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037360327&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.22587

DO - 10.18632/oncotarget.22587

M3 - Article

AN - SCOPUS:85037360327

VL - 8

SP - 107666

EP - 107677

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 64

ER -